TP53 and acute myeloid leukemia: Despite increasing recognition of this sinister biology, effective therapies for TP53 mutant AML remain limited, including cytotoxic chemotherapy [7,8], venetoclax-based regimens [6], and allogenic hematopoietic stem cell transplantation (allo-HSCT) [9].